Last update 21 Nov 2024

UCMYM802

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Target-
Mechanism-
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]
Active Indication
Bile Duct NeoplasmsBreast CancerMesothelioma, Malignant+ [4]
Inactive Indication-
Originator Organization
UTC Therapeutics (Shanghai) Co., Ltd.UTC Therapeutics (Shanghai) Co., Ltd.
Active Organization
UTC Therapeutics (Shanghai) Co., Ltd.UTC Therapeutics (Shanghai) Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with UCMYM802
NCT06256055 / RecruitingPhase 1
A First-In-Human, Single Arm, Open-label, Phase 1 Dose-Escalation Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
CTR20233925 / RecruitingPhase 1
UCMYM802注射液治疗MSLN阳性晚期实体肿瘤患者的首次人体、开放、单臂、剂量递增的I期临床试验
[Translation] A first-in-human, open-label, single-arm, dose-escalating Phase I clinical trial of UCMYM802 injection in patients with MSLN-positive advanced solid tumors
100 Clinical Results associated with UCMYM802
Login to view more data
100 Translational Medicine associated with UCMYM802
Login to view more data
100 Patents (Medical) associated with UCMYM802
Login to view more data
100 Deals associated with UCMYM802
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bile Duct NeoplasmsPhase 1
CN
UTC Therapeutics (Shanghai) Co., Ltd.UTC Therapeutics (Shanghai) Co., Ltd.
05 Mar 2024
Breast CancerPhase 1
CN
UTC Therapeutics (Shanghai) Co., Ltd.UTC Therapeutics (Shanghai) Co., Ltd.
05 Mar 2024
Mesothelioma, MalignantPhase 1
CN
UTC Therapeutics (Shanghai) Co., Ltd.UTC Therapeutics (Shanghai) Co., Ltd.
05 Mar 2024
Ovarian CancerPhase 1
CN
UTC Therapeutics (Shanghai) Co., Ltd.UTC Therapeutics (Shanghai) Co., Ltd.
05 Mar 2024
Pancreatic CancerPhase 1
CN
UTC Therapeutics (Shanghai) Co., Ltd.UTC Therapeutics (Shanghai) Co., Ltd.
05 Mar 2024
Rectal CancerPhase 1
CN
UTC Therapeutics (Shanghai) Co., Ltd.UTC Therapeutics (Shanghai) Co., Ltd.
05 Mar 2024
Mesothelin positive Solid TumorsPhase 1
CN
UTC Therapeutics (Shanghai) Co., Ltd.UTC Therapeutics (Shanghai) Co., Ltd.
20 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free